EGFR and neoplasm: Finally, we conducted responsive analyses on patients who received QL1101 or bevacizumab; the results suggested that nearly all subgroups (including age, sex, smoking history, pathology, and tumor history) showed no difference, while after PFS analyses, patients with age < 65 years, female, no smoking history, and EGFR mutations, received more OS benefit than patients with age ≥ 65 years, male, smoking history, and no EGFR mutation (Supplementary Table S2).